Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
AssigneeZogenix International Limited
InventorsStephen J. FARR, BROOKS BOYD
Life of this patent
Estimating the term…
Abstract
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Claims10
-20. (canceled)
A method of reducing or ameliorating seizures in a patient, comprising:
- administering a therapeutically affective amount of liquid formulation of fenfluramine or a pharmaceutically acceptable salt thereof;
- and
- administering a therapeutically affective amount of stiripentol thereby modulating down formation of norfenfluramine and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy selected from the group consisting of Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome, comprising:
- administering a liquid formulation of fenfluramine or a pharmaceutically acceptable salt thereof to the patient in an amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day;
- and
- administering a therapeutically affective amount of stiripentol in a liquid formulation in an amount of about 20 mg/kg/day to about 50 mg/kg/day thereby modulating down formation of norfenfluramine and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures patient diagnosed with Dravet syndrome, comprising:
- administering a therapeutically affective amount of liquid formulation of fenfluramine or a pharmaceutically acceptable salt thereof to the patient in an amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day;
- and
- administering a therapeutically affective amount of a liquid formulation stiripentol in an amount of about 20 mg/kg/day to about 50 mg/kg/day thereby modulating down formation of norfenfluramine and resulting in higher levels of fenfluramine.
Dependencies are inferred from the claim text.